Everest Organics Limited has informed the exchange about the outcome of Board meeting held on November 12, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Everest Organics' Board approved the un-audited financial results for the quarter and half year ended September 30, 2025, along with the limited review report by the statutory auditors. The Board approved the appointment of Mr. Venkata Satya Subbarao Pachigolla as an Additional Whole-time Director, subject to shareholder approval via postal ballot. Two existing directors had their designations changed: Mr. Kirankumar Rampally moved from Non-Executive Non-Independent to Independent Director, while Mr. Prasad Venkata Satya Sundara Srikakolapu moved from Independent Director to Non-Executive Non-Independent. Both designation changes are subject to shareholder approval through a postal ballot, for which a scrutinizer (M/s RPR & Associates) has been appointed.
The most notable concern for shareholders is the reclassification of an Independent Director to Non-Executive Non-Independent, which reduces independent oversight on the board – a potential governance red flag. The Q2 results and new Whole-time Director appointment may be positive, but investors should watch for the actual financial numbers and monitor how these board changes affect board independence.